Journals / Eurasian Journal of Medicine / 2021 / Cilt: 53 - Sayı: 2

The Effect of Polypharmacy on the Charlson Comorbidity Index and Katz Index in Aging People with and without Diabetes Mellitus

Pages
85–89
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients should be directed to special centersor physicians who will be scheduled for multidisciplinary treatment for the prevention of polypharmacy,especially in the aging.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The prevalence of diabetes mellitus is growing worldwide, as well as in the aging population, andits comorbidity and mortality rates are higher in aging people than they are in young people.
📊
Key Findings & Data:It has beenobserved that the number of drugs used increases in aging patients, especially in diabetic patients.
💡
Conclusion & Impact:Patients should be directed to special centersor physicians who will be scheduled for multidisciplinary treatment for the prevention of polypharmacy,especially in the aging.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The prevalence of diabetes mellitus is growing worldwide, as well as in the aging population, andits comorbidity and mortality rates are higher in aging people than they are in young people. It has beenobserved that the number of drugs used increases in aging patients, especially in diabetic patients. This studyaimed to investigate the relationship between polypharmacy and modified Charlson Comorbidity Index(CCI) and Katz Index of Independence in Activities of Daily Living (Katz ADL) scores in aging diabetic andnon-diabetic patients.Materials and Methods: This prospective study included 184 diabetic and 62 non-diabetic subjects whowere ≥65 years old. Comorbidity was determined with CCI, and dependency on daily basic activities wasassessed with Katz ADL.Results: CCI and the number of drugs were significantly higher in diabetic groups (P = .001). In all subjectsand in the diabetic group, there was a negative correlation between CCI and Katz ADL (r = −0.343, P = .001;r = −0.383, P = .001, respectively); there was a positive correlation between CCI and number of drugs (r =0.430, P = .001; r = 0.248, P = .001, respectively).Conclusion: We found an increase in the number of drugs taken by the aging patients, positively correlatedwith the CCI score. The increase in the number of drugs used is closely related to the insufficiency in dailylife activity and comorbidity, and this predicts 10-year survival. Patients should be directed to special centersor physicians who will be scheduled for multidisciplinary treatment for the prevention of polypharmacy,especially in the aging.

🔖

Cite This Article

Karandere, F., Erdal, G. S., Kocoglu, H., Kasapoglu, P., Isiksacan, N., Hursitoglu, M. (2022). The Effect of Polypharmacy on the Charlson Comorbidity Index and Katz Index in Aging People with and without Diabetes Mellitus. Eurasian Journal of Medicine, Cilt: 53 - Sayı: 2, 85–89. https://ajindex.com/articles/508829

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Ageing and health. World Health Organization. Available from: http://www.who.int/news-room/ fact-sheets/detail/ageing-and-health Accessed September 25, 2018
  2. Borissova AM, Shinkov A, Kovatcheva R, Vlahov J, Dakovska L, Todorov T. Changes in the prevalence of diabetes mellitus in bulgaria (2006- 2012). Clin Med Insights Endocrinol Diabetes. 2015;8:41-45. [Crossref] 3. Lam DW, LeRoith D. The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes. 2012;19(2): 93-96. [Crossref] 4. Caspersen CJ, Thomas GD, Boseman LA, Beckles GA, Albirght Al. Aging, diabetes, and the public health system in the United States. Am J Public Health. 2012;102(8): 1482-1497. [Crossref] 5. Geurts MME, Stewart RE, Brouwers JR, de Graeff PA. Implications of a clinical medication review and a pharmaceutical care plan of polypharmacy patients with a cardiovascular disorder. Int J Clin Pharm. 2016;38(4):808-815. [Crossref] 6. Charlesworth CJ, Smit E, Lee DS, Alramadhan F, Odden MC. Polypharmacy among adults aged 65 years and older in the United States: 1988- 2010. J Gerontol A Biol Sci Med Sci. 2015;70(8): 989-995. [Crossref] 7. Ahmed B, Nanji K, Mujeeb R, Patel MJ. Effects of polypharmacy on adverse drug reactions among geriatric outpatients at a tertiary care hospital in Karachi: a prospective cohort study. PLoS One 2014;9(11):e112133. [Crossref] 8. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002-2012. [Crossref] 9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5) 373-383. [Crossref] 10. Katz S. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc. 1983;31(12):721- 727. [Crossref] 11. Venturini CD, Engroff P, Ely LS, et al. Gender differences, polypharmacy, and potential pharmacological interactions in the elderly. Clinics (Sao Paulo). 2011;66(11):1867-1872. [Crossref] 12. Laor A, Tal S, Guller V, Zbar AP, Mavor E. The Charlson Comorbidity Index (CCI) as a mortality predictor after surgery in elderly patients. Am Surg. 2016;82(1): 22-27. [Crossref] 13. Frenkel WJ, Jongerius EJ, Mandjes-van Uitert MJ, van Munster BC, de Rooij SE. Validation of the Charlson Comorbidity Index in acutely hospitalized elderly adults: a prospective cohort study. J Am Geriatr Soc. 2014;62(2):342